Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2000

View Archived Issues

Estrogen/progestin HRT may increase risk of breast cancer, according to NCI study

Siga Pharmaceuticals announces name change

Favorable long-term data reported for AstraZeneca's atypical antipsychotic

Boehringer Ingelheim cation channel blocker tested in rat focal ischemia

Cortex receives notice of allowance for sexual dysfunction patent

Hemopure significantly eliminates need for blood transfusion in vascular surgery

FDA grants Merck & Co. marketing exclusivity extension for Vasotec

Recently approved AmBisome label includes claim of superior safety compared to Abelcet

New GRF analogue from Theratechnologies shows promising phase Ib trial results

New study to evaluate FolateScan efficacy in detecting ovarian cancer

Acorda to commence phase II clinical trial of lead product for spinal cord injury

FDA clears small-molecule angiogenesis inhibitor for clinical testing

Positive phase III trial results reported by Genelabs for lupus treatment

MorphoSys achieves milestone in anticancer collaboration with GPC

Valentis highlights developments during second quarter

Ligand and Organon sign research agreement for progesterone receptor-modulating agents

Dura makes acquisition offer to Spiros, announces intentions regarding R&D

New gold complexes for X-ray therapy and imaging designed at Meiji Seika

Transmucosal clemastine under study at Nastech for motion sickness

Agents with nanomolar affinity for the MDR binding site jointly discovered by Japanese labs

German researchers disclose new agents for hypertension

Antiallergic agents from SB act as CCR3 receptor antagonists

Active Biotech reports on quinolines particularly useful in MS

New leader in regenerative medicine to result from three-way merger of Boston biotech companies

Anti-gpIIb/IIIa MAb fragment proves effective and safe in rat model of embolic stroke

Stroke news: DuPont gpIIb/IIIa antagonist shows promise in ischemic stroke

Study shows popular herbal supplement compromises the efficacy of anti-HIV drugs

Endonuclease activity as a potential therapeutic target for preventing neuronal apoptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...